Insilico Biotechnology AG and Teva Pharmaceutical Industries Ltd. announced an agreement to apply Insilico’s technology for predictive biomanufacturing to create and implement more efficient production processes of Teva’s biopharmaceutical therapeutics.
The ever increasing demand of high-quality biopharmaceutical therapies such as monoclonal antibodies requires more than ever highly efficient and robust production technologies. Simultaneously the digital transformation of the biopharmaceutical sector generates tremendous amounts of data from bioprocessing which represent an enormous value to be capitalized on.
Insilico’s solutions for predictive biomanufacturing are one of the key technologies to convert this value into higher quality therapies and to bring them faster to market. Insilico’s Digital Twins of biopharmaceutical production processes employ metabolic models of producer organisms in combination with flexible process models and artificial intelligence to create optimized production processes by computational simulations.
As a leading provider of high-quality medicines for nearly all therapeutic areas, Teva uses the most efficient and innovative technologies for best-in-class production of their therapeutic agents.
By complementing our process development capabilities with Insilico’s unique technology for digital bioprocess development we can accomplish robust and efficient production of our biologics pipeline faster. Saving experimental efforts and time perfectly fits the accelerated timelines in clinical development that we are seeing now and even more in the future,
says Jason Bock,
VP of Biologics CMC at Teva.
We are proud to support Teva with our predictive solutions to speed-up the key steps in bioprocess development. The use of Insilico Digital Twins is able to transform the enormous wealth of process data generated every day into measurable improvements. We are absolutely convinced that this collaboration is a major step in predictive biomanufacturing and towards the future of biologics production,
CEO of Insilico Biotechnology, adds
The collaboration will run for three years and will be based at Insilico’s sites in Stuttgart, Germany and at Teva’s West Chester, PA, USA, location.